Perry Maxwell
YOU?
Author Swipe
View article: KRASFormer: a fully vision transformer-based framework for predicting KRAS gene mutations in histopathological images of colorectal cancer
KRASFormer: a fully vision transformer-based framework for predicting KRAS gene mutations in histopathological images of colorectal cancer Open
Detecting the Kirsten Rat Sarcoma Virus ( KRAS ) gene mutation is significant for colorectal cancer (CRC) patients. The KRAS gene encodes a protein involved in the epidermal growth factor receptor (EGFR) signaling pathway, and mutations in…
View article: True-T – Improving T-cell response quantification with holistic artificial intelligence based prediction in immunohistochemistry images
True-T – Improving T-cell response quantification with holistic artificial intelligence based prediction in immunohistochemistry images Open
The immune response associated with oncogenesis and potential oncological ther- apeutic interventions has dominated the field of cancer research over the last decade. T-cell lymphocytes in the tumor microenvironment are a crucial aspect of…
View article: Supplementary Figure Legends 1-2 from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival
Supplementary Figure Legends 1-2 from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival Open
PDF file - 70K
View article: Data from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival
Data from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival Open
Up to 50% of epithelial ovarian cancers (EOC) display defects in the homologous recombination (HR) pathway. We sought to determine the ramifications of the homologous recombination–deficient (HRD) status on the clinicopathologic features, …
View article: Data from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival
Data from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival Open
Up to 50% of epithelial ovarian cancers (EOC) display defects in the homologous recombination (HR) pathway. We sought to determine the ramifications of the homologous recombination–deficient (HRD) status on the clinicopathologic features, …
View article: Supplementary Figure Legends 1-2 from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival
Supplementary Figure Legends 1-2 from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival Open
PDF file - 70K
View article: Supplementary Figure 1 from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival
Supplementary Figure 1 from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival Open
PDF file - 103K, HR status and correlation with ex vivo cytotoxicity to PARP inhibitors. A, schema outlining study demontrating tight correlation between HR deficiency and sensitivity to PARP inhibitor for both epithelial EOCs and other HR…
View article: Supplementary Figure 2 from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival
Supplementary Figure 2 from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival Open
PDF file - 62K, RAD51 foci and ex vivo cytotocicity in HR competent and HR deficient primary cultures A. Box plot showing cytotoxicity to 10 muM rucaparib B. Box plot showing RAD51 foci formation after 24 hr exposure to rucaparib or hydrox…
View article: Supplementary Figure 1 from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival
Supplementary Figure 1 from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival Open
PDF file - 103K, HR status and correlation with ex vivo cytotoxicity to PARP inhibitors. A, schema outlining study demontrating tight correlation between HR deficiency and sensitivity to PARP inhibitor for both epithelial EOCs and other HR…
View article: Supplementary Figure 2 from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival
Supplementary Figure 2 from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival Open
PDF file - 62K, RAD51 foci and ex vivo cytotocicity in HR competent and HR deficient primary cultures A. Box plot showing cytotoxicity to 10 muM rucaparib B. Box plot showing RAD51 foci formation after 24 hr exposure to rucaparib or hydrox…
View article: Technical note on the exploration of COVID-19 in autopsy material
Technical note on the exploration of COVID-19 in autopsy material Open
Interrogation of immune response in autopsy material from patients with SARS-CoV-2 is potentially significant. We aim to describe a validated protocol for the exploration of the molecular physiopathology of SARS-CoV-2 pulmonary disease usi…
View article: ICOSeg: Real-Time ICOS Protein Expression Segmentation from Immunohistochemistry Slides Using a Lightweight Conv-Transformer Network
ICOSeg: Real-Time ICOS Protein Expression Segmentation from Immunohistochemistry Slides Using a Lightweight Conv-Transformer Network Open
In this article, we propose ICOSeg, a lightweight deep learning model that accurately segments the immune-checkpoint biomarker, Inducible T-cell COStimulator (ICOS) protein in colon cancer from immunohistochemistry (IHC) slide patches. The…
View article: ICOS Protein Expression Segmentation: Can Transformer Networks Give Better Results?
ICOS Protein Expression Segmentation: Can Transformer Networks Give Better Results? Open
Biomarkers identify a patients response to treatment. With the recent advances in artificial intelligence based on the Transformer networks, there is only limited research has been done to measure the performance on challenging histopathol…
View article: General Roadmap and Core Steps for the Development of AI Tools in Digital Pathology
General Roadmap and Core Steps for the Development of AI Tools in Digital Pathology Open
Integrating artificial intelligence (AI) tools in the tissue diagnostic workflow will benefit the pathologist and, ultimately, the patient. The generation of such AI tools has two parallel and yet interconnected processes, namely the defin…
View article: Identifying mismatch repair‐deficient colon cancer: near‐perfect concordance between immunohistochemistry and microsatellite instability testing in a large, population‐based series
Identifying mismatch repair‐deficient colon cancer: near‐perfect concordance between immunohistochemistry and microsatellite instability testing in a large, population‐based series Open
Aims Establishing the mismatch repair (MMR) status of colorectal cancers is important to enable the detection of underlying Lynch syndrome and inform prognosis and therapy. Current testing typically involves either polymerase chain reactio…
View article: Systematic evaluation of PAXgene® tissue fixation for the histopathological and molecular study of lung cancer
Systematic evaluation of PAXgene® tissue fixation for the histopathological and molecular study of lung cancer Open
Whilst adequate for most existing pathological tests, formalin is generally considered a poor DNA preservative and use of alternative fixatives may prove advantageous for molecular testing of tumour material; an increasingly common approac…
View article: Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies
Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies Open
Our data show that SRCCa phenotype comprises two distinct genotypes. The MSI+/CIMP+/BRAF V600E+/CD3+/PDL1+ hypermethylated genotype is an ideal candidate for immune checkpoint inhibitor therapy. In addition, one fourth of SRCCa cases can p…
View article: Erythropoietin drives breast cancer progression by activation of its receptor EPOR
Erythropoietin drives breast cancer progression by activation of its receptor EPOR Open
Breast cancer is a leading cause of cancer-related deaths. Anemia is common in breast cancer patients and can be treated with blood transfusions or with recombinant erythropoietin (EPO) to stimulate red blood cell production. Clinical stud…
View article: Tissue-based next generation sequencing: application in a universal healthcare system
Tissue-based next generation sequencing: application in a universal healthcare system Open
In the context of solid tumours, the evolution of cancer therapies to more targeted and nuanced approaches has led to the impetus for personalised medicine. The targets for these therapies are largely based on the driving genetic mutations…
View article: NGS gene mutation detection using the Ion AmpliSeq Cancer Panel in colorectal carcinoma.
NGS gene mutation detection using the Ion AmpliSeq Cancer Panel in colorectal carcinoma. Open
NGS gene mutation detection using the Ion AmpliSeq Cancer Panel in colorectal carcinoma.
View article: Validation of immunocytochemistry as a morphomolecular technique
Validation of immunocytochemistry as a morphomolecular technique Open
Immunocytochemistry (ICC) is a long‐established means for clinical laboratories to investigate material for which it is difficult to obtain tissue samples. Unlike immunohistochemistry (IHC), the cells do not retain surrounding tissue envir…